By Stephen Nakrosis 
 

The Janssen Pharmaceutical Cos. of Johnson & Johnson on Thursday said a European Medicines Agency committee gave a positive opinion recommending the approval of Darzalex subcutaneous formulation for certain adult patients with myeloma.

The company said the EMA's Committee for Medicinal Products for Human Use recommended approving the Darzalex, or daratumumab, formulation "for the treatment of adult patients with multiple myeloma in frontline and relapsed/refractory settings."

The company said the subcutaneous formulation reduces the amount of time it takes for patients to receive the treatment from hours to five minutes or less, and added "if approved, daratumumab subcutaneous formulation will be the first monoclonal antibody approved in Europe for subcutaneous administration for patients with multiple myeloma."

 

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

April 30, 2020 16:06 ET (20:06 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Johnson and Johnson Charts.